Nonalcoholic Fatty Liver and T2DM – The Intersection of Endocrinology and Hepatology

Madrigal Pharmaceuticals |
Tuesday

Chairs:
Cyrielle Caussy (FRA)
Jörn Schattenberg (GER)

12:45 – 12:50Why should diabetologists screen for significant fibrosis in patient with T2DM Jörn Schattenberg (GER)
12:50 – 13:05How to screen T2DM patients for significant fibrosis? Cyrielle Caussy (FRA)
13:05 – 13:15

How to set up a clinical pathways from diabetology to hepatology?

Cyrielle Caussy (FRA)
Jörn Schattenberg (GER)